Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 932 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Immune interception represents an exciting opportunity to stop cancer in its... September 16, 2025 When Ellen Found Out There Was A Grieving Mother In The... March 12, 2019 For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge January 8, 2020 Percentage of Cancer Patients Who Are Eligible for and Respond to... April 15, 2021 Load more HOT NEWS Study Says Exercise Combats Side Effects of Chemo and Other Meds... 5 Tips to Move Beyond the Bedside Cómo mi diagnóstico de cáncer a los 17 años cambió mi... Beating the Heat with Beets
